cd19 t-hank
Cell therapyexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 16, 2019 (NCT04052061)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07125872 | Phase 2 | Aug 19, 2025 | ImmunityBio, Inc. |
| NCT06334991 | Phase 1 | Aug 23, 2024 | ImmunityBio, Inc. |
| NCT05618925 | Phase 1 | Nov 15, 2022 | ImmunityBio, Inc. |
| NCT04052061 | Phase 1 | Sep 16, 2019 | NantWorks |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunityBio, Inc. | For profit | 3 | 3 | 2 | 2022 |
| NantWorks | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1